Annual Report for Financial Year 2024-25

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.4%Reaction day

₹214.70

prior close

₹225.40

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-4.2% vs market

Other Textile Products peers, median of 175sector-0.1%-4.3% vs sector

On the reaction day the stock moved 4.2 pts less than Nifty Microcap 250 and 4.3 pts less than its Other Textile Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.4-0.2-4.2-0.1-4.3

Next day

-2.2+1.1-3.3-0.1-2.1

-4.9+2.0-6.8+0.6-5.4

-9.6+3.0-12.6+0.5-10.1

-14.1+2.3-16.4+0.2-14.4

-13.8+2.3-16.1+1.0-14.8

-18.7+2.9-21.7+0.6-19.4

15d

-20.6+5.3-25.9+3.1-23.7

-4.5-0.3-4.3-0.6-3.9

—+3.8—-0.9—

—+0.2—-5.7—

UpDownMarket · Nifty Microcap 250Sector · Other Textile Products peers, median of 175Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Skybiotech Healthcare Ltd has filed its Annual Report for the financial year 2024-25 with BSE. The filing covers the full-year audited results and disclosures required under listing regulations. Specific financial details such as revenue, profit, auditor opinions, and balance sheet figures are not available in the provided headline and would need to be reviewed from the actual annual report document.

Likely market impact

The filing itself is a routine compliance disclosure and is unlikely to have an immediate impact on the stock price. Investors should review the attached annual report for detailed financial performance, auditor remarks, and any material developments before drawing conclusions.